Athersys, Inc. (ATHX)
Market Cap | 25.56M |
Revenue (ttm) | 6.02M |
Net Income (ttm) | -81.24M |
Shares Out | 17.21M |
EPS (ttm) | -7.90 |
PE Ratio | n/a |
Forward PE | 0.86 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 103,768 |
Open | 1.56 |
Previous Close | 1.51 |
Day's Range | 1.44 - 1.56 |
52-Week Range | 0.50 - 33.25 |
Beta | -0.95 |
Analysts | Sell |
Price Target | 3.06 (+112.5%) |
Earnings Date | Mar 21, 2023 |
About ATHX
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as ... [Read more]
Financial Performance
In 2021, Athersys's revenue was $5.51 million, an increase of 282.92% compared to the previous year's $1.44 million. Losses were -$86.96 million, 10.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ATHX stock is "Sell." The 12-month stock price forecast is $3.06, which is an increase of 112.50% from the latest price.
News

Athersys to Participate in International Stroke Conference and BioProcess International
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its p...

Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in...

Athersys Provides MultiStem Clinical Update
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, today provided an update on ongoing cl...

Athersys Appoints Joseph Nolan to Its Board of Directors
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Jos...

Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and nine months ended September 30, 2022 and provided a business update.

Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.'s Biotech Conference
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in t...

Athersys, Inc. Announces Closing of $5.5 Million Confidentially Marketed Public Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced confidentially marketed public offering with healthcare-focused U.S. institutional i...

Athersys Reschedules Third Quarter Conference Call to November 15
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it intends to file ...

Athersys, Inc. Announces Pricing of $5.5 Million Public Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced the pricing of its previously announced "best efforts" public offering of 5,004,545 shares of co...

Athersys, Inc. Announces Proposed Public Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lie...

Athersys to Host Third Quarter Financial Results Call
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results.

Athersys to Present at 2022 Cell & Gene Meeting on the Mesa Conference and Attend 14th World Stroke Congress in October
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in t...

Athersys to Host Business Update Conference Call on October 6th
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business ...

Athersys Amends Securities Purchase Agreement in Connection with Recent Registered Direct Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it has entered into...

The Three Best Anti-Aging Stocks to Buy in September
Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those ...

ATHX, PETS: The Top 5 Short Squeeze Stocks to Watch This Week
Source: g0d4ather / Shutterstock.com We're starting off another week with a deep dive into the short squeeze stocks to watch! Short squeeze stocks have been popular with traders in recent months as th...

Athersys Announces 1-for-25 Reverse Stock Split
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it will be executin...

Athersys, Inc. Announces Closing of $12 Million Registered Direct Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced the closing of its previously announced registered direct offering with a single healthcare-focused U.S. institutional investo...

Athersys, Inc. Announces $12 Million Registered Direct Offering
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) today announced that it has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor for the purchase ...

Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second ...

Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARS--Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRR...

Athersys Appoints Kasey Rosado as Interim Chief Financial Officer
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys Appoints Kasey Rosado as Interim Chief Financial Officer - Brings Operational Excellence and Financial Experience to Leadership Team

Athersys to Host Second Quarter Financial Results Call
CLEVELAND--(BUSINESS WIRE)---- $ATHX #MultiStem--Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022...

Athersys and Aspire Capital Fund Terminate Relationship
CLEVELAND--(BUSINESS WIRE)---- $ATHX--Athersys, Inc. (Nasdaq: ATHX) today announced that its equity purchase agreement with Aspire Capital Fund LLC (Aspire Capital) has been terminated. The Company co...

Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures
CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX--In connection with the Company's cost-cutting and restructuring initiatives, the Board of Directors approved reducing its size from 10 to 5 members.